相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of Long-Term Effects of Nanoparticles in a Microcarrier Cell Culture System
Maria Mrakovcic et al.
PLOS ONE (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737
Adrian P. Wiegmans et al.
CANCER RESEARCH (2011)
Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL
Vitaliy O. Kaminskyy et al.
CARCINOGENESIS (2011)
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells
Eun-Sil Sung et al.
APOPTOSIS (2010)
Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
Yanyuan Wu et al.
BMC CANCER (2010)
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
Andelko Hrzenjak et al.
MOLECULAR CANCER (2010)
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner et al.
Clinical Epigenetics (2010)
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
Ailsa J. Frew et al.
CANCER LETTERS (2009)
Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Gliomas
Agnes Elias et al.
CLINICAL CANCER RESEARCH (2009)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation
Daniela Carlisi et al.
EUROPEAN JOURNAL OF CANCER (2009)
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma
Joanna M. Lubieniecka et al.
CANCER RESEARCH (2008)
Modulation of TRAIL-induced apoptosis by HDAC inhibitors
Simone Fulda
CURRENT CANCER DRUG TARGETS (2008)
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway
A. Hrzenjak et al.
JOURNAL OF PATHOLOGY (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL
S. I. Bae et al.
ONCOGENE (2008)
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Ricky W. Johnstone et al.
NATURE REVIEWS CANCER (2008)
Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival
Hui Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells
Juergen Sonnemann et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2007)
Histone deacetyllase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondriall and Fas (Cd95) signalling in head and neck squamous carcinorna cells
Ann M. Gillenwater et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Caspase-8-mediated apoptosis in human RPE cells
Ping Yang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
The role of histone deacetylases (HDACs) in human cancer
Santiago Ropero et al.
MOLECULAR ONCOLOGY (2007)
CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme
Ramon Martinez et al.
CARCINOGENESIS (2007)
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
Trine Lillehammer et al.
JOURNAL OF GENE MEDICINE (2007)
Lack of Gnas epigenetic changes and pseudohypoparathyroidism type Ib in mice with targeted disruption of syntaxin-16
Leopold F. Frohlich et al.
ENDOCRINOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL
Lisa M. Butler et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
TRAIL-induced apoptosis proceeding from caspase-3-dependent and -independent pathways in distinct HeLa cells
Juqiang Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
SAHA-sensitized prostate cancer cells to TNFα-related apoptosis-inducing ligand (TRAIL):: Mechanisms leading to synergistic apoptosis
Vijavabaskar Lakshmikanthan et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
SB Baylin et al.
NATURE REVIEWS CANCER (2006)
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
TE Fandy et al.
NEOPLASIA (2005)
Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer
P Horak et al.
MOLECULAR CANCER RESEARCH (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
A novel immortalized human endometrial stromal cell line with normal progestational response
G Krikun et al.
ENDOCRINOLOGY (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs
S Tomek et al.
GYNECOLOGIC ONCOLOGY (2004)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway:: Absolute requirement for removal of caspase-6 prodomain
V Cowling et al.
CELL DEATH AND DIFFERENTIATION (2002)
Differential inactivation of caspase-8 in lung cancers
N Shivapurkar et al.
CANCER BIOLOGY & THERAPY (2002)
Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer
S Fulda et al.
ONCOGENE (2001)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
T Teitz et al.
NATURE MEDICINE (2000)
分享论文
